Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
09/15/2021 09/16/2021 09/17/2021 09/20/2021 09/21/2021 Date
8125(c) 8141(c) 8063(c) 8559(c) 8675 Last
1 488 261 1 611 986 3 608 241 3 934 686 1 381 930 Volume
-0.06% +0.20% -0.96% +6.15% +1.36% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 35 401 M - -
Net income 2021 5 006 M - -
Net Debt 2021 24 250 M - -
P/E ratio 2021 32,7x
Yield 2021 2,41%
Sales 2022 42 707 M - -
Net income 2022 8 094 M - -
Net Debt 2022 19 739 M - -
P/E ratio 2022 21,7x
Yield 2022 2,50%
Capitalization 181 B 181 B -
EV / Sales 2021 5,80x
EV / Sales 2022 4,70x
Nbr of Employees 76 100
Free-Float 96,3%
More Financials
Company
AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with... 
Read more
Sector
Pharmaceuticals
Calendar
09/20Presentation
More about the company
Ratings of AstraZeneca PLC
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about ASTRAZENECA PLC
10:06aShangula Rages Against West's Vaccine Nationalism
AQ
08:35aASTRAZENECA : India calls new UK COVID-19 vaccine rules 'discriminatory'
AQ
07:02aASTRAZENECA : Investment will transform development and commercialisation of new medicines..
PU
06:23aEUROPEAN MIDDAY BRIEFING : Stocks Rebound But -2-
DJ
05:42aASTRAZENECA : to Invest $360 Million in New Irish Manufacturing Facility
MT
02:51aCapital.com Announces Top Hire to Drive Growth in Asia
DJ
02:45aAstraZeneca to invest $360 million in Irish drug manufacturing site
RE
02:25aASTRAZENECA : Plans New $360 Million Irish Manufacturing Site
MT
02:12aASTRAZENECA : to invest $360m in advanced manufacturing facility in Ireland
PU
12:23aAstraZeneca to Build $360 Million Manufacturing Plant in Dublin
DJ
12:14aEMEA MORNING BRIEFING : Stocks to Rebound as -2-
DJ
09/20Healthcare Shares Fall Amid Concerns About Delta Variant -- Healthcare Roundup
DJ
09/20THE LATEST : EU official: US isn't being loyal or transparent
AQ
09/20ADRs Close Lower, AstraZeneca Rises
DJ
09/20ASTRAZENECA : White House plan to allow foreign visitors silent on easing Canada-U.S. rest..
AQ
More news
News in other languages on ASTRAZENECA PLC
10:29aASTRAZENECA : Tourismus hofft auf Schub mit Öffnung des Reisemarktes USA
06:44aUSA : impegno per vaccinare Paesi poveri deve affrontare sfide logistiche
06:22aASTRAZENECA : un nouveau site de production à 360 millions de dollars
05:59aPLANÈTE BOURSE : La revue de presse du mardi 21 septembre 2021
05:42aAstraZeneca va investir 360 millions de dollars dans un nouveau site de production en I..
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Analysis
Biocon unit plans 15% stake sale to Serum Institute for access to vaccines
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 116,93 $
Average target price 135,96 $
Spread / Average Target 16,3%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC16.86%181 312
JOHNSON & JOHNSON4.09%431 227
ROCHE HOLDING AG10.52%321 941
PFIZER, INC.19.23%247 816
NOVO NORDISK A/S48.69%229 255
ELI LILLY AND COMPANY37.20%210 000